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Abstract 
This paper examines the implications of the single market in insurance for regulation 
of private health insurance in the European Union. It considers areas of uncertainty in 
interpreting the third non-life insurance directive, particularly with regard to when and 
how governments may regulate private health insurance, and questions the Directive’s 
capacity to promote consumer and social protection in health insurance markets. The 
Directive reflects the regulatory norms of the late 1980s and early 1990s, when 
boundaries between ‘social security’ and ‘normal economic activity’ were still 
relatively well defined in most member states. Today these boundaries are 
increasingly blurred, and as governments look to private health insurance to ease 
pressure on public budgets, uncertainty about the scope of the Directive and concerns 
about its restrictions on material regulation are likely to grow. 
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1.  Introduction 
 
The European Union (EU) has traditionally considered health and health systems to 
be subject to the subsidiarity principle, a view confirmed by successive European 
treaties. In practice, however, there are a number of health-related areas in which EU 
policies directly or indirectly provide a framework for national legislation or override 
national competence all together. Obvious cases involve public health activities such 
as epidemiological surveillance, control of communicable diseases and rules about 
labelling of tobacco products. In other areas the influence of EU law, although 
significant and growing, has been less visible; for example, the free movement of 
people in search of treatment abroad and the freedom to provide health services, 
including insurance, across national borders (Mossialos and McKee 2002). 
 
In 1992 the European Commission (hereafter referred to as ‘the Commission’) 
established a regulatory framework intended to enhance competition and consumer 
choice in markets for all types of non-life insurance including, for the first time, 
markets for health insurance. To facilitate the free movement of health and other non-
life insurance services throughout the single European market, the introduction of the 
third non-life insurance directive removed barriers to entry and outlawed various 
forms of government intervention. For example, governments can no longer impose 
price and product controls in private health insurance markets, except where these 
form a ‘partial or complete alternative’ to statutory health insurance (European 
Communities 1992). 
 
This paper examines the implications of the single market in insurance for regulation 
of private health insurance in the European Union. In doing so it considers areas of 
uncertainty in interpreting the third non-life insurance directive (referred to here as 
‘the Directive’), particularly with regard to when and how governments may regulate 
private health insurance. As in other spheres of EU legislation, interpretation largely 
rests on the jurisprudence of the European Court of Justice (ECJ), so clarity may 
come at a high cost and after considerable delay. The paper also questions the 
Directive’s capacity to promote consumer and social protection in health insurance 
markets. In many ways the Directive reflects the regulatory norms of the late 1980s 
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and early 1990s, a time when boundaries between ‘social security’ and ‘normal 
economic activity’ were still relatively well defined in most member states (White 
1999). Today these boundaries are increasingly blurred, and as governments in old 
and new member states look to private health insurance to ease pressure on public 
budgets, uncertainty about the scope of the Directive and concerns about its 
restrictions on regulation are likely to grow. 
 
Our study is based, where possible, on discussion of ECJ rulings and cases in which 
the Commission has considered national regulation of private health insurance to have 
infringed the Directive or contravened other forms of EU legislation. Where actual 
examples are lacking, our analysis is, inevitably, more speculative. In the following 
section we summarise the main changes brought about by the Directive and its initial 
impact on regulation of private health insurance in the European Union. A subsequent 
section examines the issue of uncertainty as to when and how governments can 
intervene in private health insurance markets (that is, where health insurance is 
voluntary and paid for privately by individuals and/or their employers). The paper 
concludes with a discussion of key points. 
 
 
2.  The introduction of the third non-life insurance directive and regulation of 
private health insurance in the European Union 
 
Markets for health insurance suffer from inefficiencies triggered by the nature of 
health risks, asymmetrical information between insurers, consumers and regulators 
and the absence of perfect competition (Barr 1998). As a result, voluntary (private) 
insurance rarely achieves an adequate quantity or quality of population coverage, a 
failure starkly illustrated in the United States, where one in three adults under the age 
of 65 has no health insurance, sporadic cover or cover that exposes them to high out 
of pocket health care costs (Schoen et al 2005). 
 
For efficiency and equity reasons governments intervene in markets for health 
insurance in several ways. Many choose to organise statutory (public) health 
insurance, typically combining compulsory risk pooling on a national or regional 
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scale with rules concerning levels of pre-payment through taxation or earmarked 
‘contributions’, the range of services to be covered and the provision of benefits in 
kind (Rice 2001). Some allow health insurance to operate on a private basis subject to 
regulation intended to protect consumers and improve access. Less direct intervention 
may involve subsidising the price of private cover or favouring particular insurers – 
for example, by giving tax breaks to non-profit entities. 
 
The majority of EU member states provide universal or near universal public 
coverage for health as part of a wider system of ‘social protection’. Private insurance 
offering ‘supplementary’ cover (see Table 1) accounts for less than 5% of total 
expenditure on health (Organisation for Economic Co-operation and Development 
2003). In some member states, however, private insurance also contributes to social 
protection, providing cover that substitutes for or complements statutory insurance. 
Without this ‘substitutive’ and ‘complementary’ private cover, which may be 
purchased by large proportions of the population and usually accounts for 10-20% of 
total health expenditure, people would not be sufficiently protected from financial 
risks associated with ill health. 
 
Historically, the extent to which EU governments regulated private health insurance 
was determined by the role of private cover in the health system, aspects of market 
structure (such as the number and type of insurers in operation) and political ideology. 
Two broad approaches prevailed: minimal financial or prudential regulation of 
supplementary markets, focusing on solvency levels, and heavier material regulation 
of substitutive markets, emphasising control of prices and products. While both 
approaches aimed to protect consumers from insurer insolvency1, material regulation 
also endeavoured to ensure access to health care. Under the subsidiarity principle 
governments were free to decide on the appropriate form of regulation required in a 
given context. 
 
                                                     
1
 Financial or prudential regulation focuses on ex post scrutiny of an insurer’s financial returns on 
business. Material or contract regulation involves ex ante scrutiny of an insurer’s policy conditions and 
premium rates on the grounds that this eliminates the potential for insolvency. 
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Table 1 The role of private health insurance in EU health systems 
Role Coverage and examples 
Substitutive For people excluded from some or all aspects of statutory 
cover (eg higher-income households in the Netherlands prior 
to 2006) or allowed to choose between statutory and private 
cover (eg higher-income households in Germany) 
Complementary Services excluded (eg dental care, alternative treatment) or 
only partially covered by the state (eg statutory user charges) 
Supplementary Increased choice of provider and faster access to services 
Source: Mossialos and Thomson 2004 
 
In the last thirty years the Commission has successfully removed this freedom by 
introducing a series of directives aimed at creating a single market in insurance 
(European Communities 1973; European Communities 1988; European Communities 
1992). The first and second generation of insurance directives were limited to the 
cover of ‘large risks’ of a commercial nature considered small enough, in relation to 
the size or status of their policy holders, not to require special protection (for example, 
aviation or marine insurance and re-insurance) (Merkin and Rodger 1997; Mabbett 
2000). ‘Mass risks’ involving individuals and small businesses were excluded on the 
grounds that they required special protection because their policy holders would not 
normally have the ability to judge all the complexities of the obligation they 
undertook in an insurance contract (Nemeth 2001). The third generation of insurance 
directives extended the application of single market legislation to all types of risks, 
including mass risks such as health insurance. 
 
The third non-life insurance directive gives insurers full freedom to provide services 
throughout the European Union, with or without a branch presence, through the 
introduction of a single system for the authorisation and financial supervision of an 
insurance undertaking by the member state in which the undertaking has its head 
office (‘home country control’); the mutual recognition of systems of authorisation 
and financial supervision; and the harmonisation of minimum solvency standards 
(European Communities 1992). ECJ case law confirms that insurance activities fall 
under the scope of the Directive when they are carried out by insurance undertakings 
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at their own risk, following insurance techniques, and on the basis of contractual 
relationships governed by private law (European Court of Justice 1991; European 
Court of Justice 2000; Hatzopoulos 2002). 
 
To protect the freedoms outlined above and prevent barriers to competition, the 
Directive brought about three key changes for private health insurance. First, by 
requiring governments to abolish existing product and price controls, the Directive 
accords primacy to the financial approach to regulation, rendering the material model 
redundant and, in some cases, illegal. Second, it requires governments to liberalise 
markets for private health insurance, opening them to competition at national and EU 
levels. Third, it prevents governments from discriminating among insurers on the 
basis of legal status. 
 
Material control in the form of national rules requiring the prior approval or 
systematic notification of policy conditions, premium rates, proposed increases in 
premium rates and printed documents insurers use in their dealings with policy 
holders are no longer permitted (articles 29 and 39). Such rules played an important 
regulatory function in several countries, notably France, Germany and Italy. However, 
most member states amended existing laws or passed new laws to comply with the 
Directive. Legislative changes generally involved the introduction of tighter solvency 
controls, although some also resulted in the loosening or outright abolition of price 
and product controls. France proved to be the exception in this respect, contravening 
the Directive by continuing to insist that insurers notify the supervisory authority 
when they launched a new product. The ECJ ruled against the French government in 
May 2000 (European Commission 2000; European Court of Justice 2000). 
 
Although the Directive prevents governments from introducing regulatory measures 
that go beyond solvency requirements, member states do retain limited residual 
powers to protect policy holders. For example, if the home supervisory authority fails 
to prevent an insurer from infringing the host country’s domestic law, the host 
supervisory authority may take action, but only as a last resort (Merkin and Rodger 
1997). More importantly, the host supervisory authority may impose specific 
measures, in the form of restrictions on insurance contracts, in the interest of the 
‘general good’, if contracts covering health risks ‘serve as a partial or complete 
  9 
alternative to health cover provided by the statutory social security system’ (article 
54.1). Where this is the case, the government can require private insurers to ‘comply 
with the specific legal provisions adopted by that member state to protect the general 
good in that class of insurance’ (article 54.1) (European Communities 1992). 
 
Article 54.2 and recitals to the Directive lists the types of legal provisions that may be 
introduced if private cover provides a partial or complete alternative to statutory 
cover: open enrolment, community rating, lifetime cover, policies standardised in line 
with the cover provided by the statutory health insurance scheme at a premium rate at 
or below a prescribed maximum, participation in risk equalisation schemes (referred 
to as ‘loss compensation schemes’) and the operation of private health insurance on a 
technical basis similar to life insurance. Measures taken to protect the general good 
must be shown to be necessary and proportional to this aim; not unduly restrict the 
right of establishment or the freedom to provide services; and apply in an identical 
manner to all insurers operating within a member state. 
 
Governments in Germany and the Netherlands have used article 54.1 to justify 
intervention in their substitutive markets, where risk selection by private insurers 
prevents some older people and people with chronic illnesses from buying an 
adequate and affordable level of private cover (Wasem 1995; Rupprecht et al 2000). 
Regulatory measures in both countries (prior to 2006 in the Netherlands) include the 
provision of lifetime cover, the introduction of policies with mandatory pooling, 
standardised minimum benefits, guaranteed prices and the establishment of direct or 
indirect cross subsidies from those with private to those with statutory coverage. 
German private insurers are subject to further regulation concerning the way in which 
they fund substitutive cover (on a similar basis to life insurance) and the provision of 
information to potential and existing policy holders. The Irish market is also tightly 
regulated; insurers must offer open enrolment with community rating and the Minister 
of Health has the power to trigger a risk equalisation scheme if this is deemed 
necessary by an independent regulatory body. 
 
In contrast, regulation of most markets for complementary and supplementary cover 
tends to focus on ex post scrutiny of financial returns on business to ensure that 
insurers remain solvent. Insurers are permitted to reject applications for cover, 
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exclude cover of or charge higher premiums for individuals with pre-existing 
conditions, rate premiums according to risk, provide non-standardised benefit 
packages and offer annual contracts, while benefits are usually provided in cash rather 
than in kind. 
 
 
3.  Implications for government intervention in health insurance markets 
 
At first sight the Directive appears to give governments significant scope for 
regulating private health insurance under the general good principle, which broadly 
refers to any legislation aimed at protecting consumers. On closer examination, 
however, interpretation of the principle is shown to be problematic in two areas: first, 
the issue of what is meant by complete or partial alternative to statutory health 
insurance; and second, what types of intervention are necessary and proportional. 
 
These problems arise because there is no agreed definition of the general good; 
interpretation relies on ECJ case law. Following complaints about the absence of a 
definition, the Commission tried to clarify when and how the general good might be 
invoked in the insurance sector, but its interpretive communication failed to provide 
new information (European Commission 2000). Calls for further clarification persist 
on the grounds that the lack of a definition creates legal uncertainty, while the process 
of testing questionable use of the general good through the courts is prohibitively 
lengthy and expensive (Mossialos and Thomson 2004). We discuss interpretation of 
the general good in relation to when and how governments can intervene in markets 
for private health insurance. 
 
When can governments intervene? 
Uncertainty about when the general good can be invoked to justify material regulation 
arises from the need to distinguish between private health insurance that serves as a 
partial or complete alternative to statutory health insurance, as set out in article 54.1, 
and private cover that does not fall into such a category. Circumstantial factors 
suggest that the distinction hinges on whether or not private health insurance plays a 
substitutive role. For example, article 54 was inserted during negotiations prior to the 
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drafting of the Directive at the instigation of the German, Dutch and Irish 
governments (Association Internationale de la Mutualité 1999). As a result of 
lobbying from member states with substitutive markets, the regulatory measures 
outlined in article 54.2 are an exact match of those already in place in Germany, the 
Netherlands (prior to 2006) and Ireland, and so far the stringent regulatory 
frameworks applied to private insurers in these three countries have not been 
challenged by the Commission. 
 
Recent policy developments in the Netherlands shed further light on this crucial 
distinction. Since the late 1990s successive governments have put forward proposals 
to replace the existing dual system of statutory cover for lower earners and voluntary 
private cover for higher earners with a single, universal system of health insurance. 
Uncertainty about how to interpret article 54 persuaded a previous government to 
propose a public rather than private system (Maarse 2002), but the current 
government introduced a private system in 2006. Under the new system health 
insurance is operated by private insurers and governed by private law. Regulatory 
measures include open enrolment, lifetime cover, community-rated premiums set by 
insurers, a package of minimum benefits in kind or cash defined by the government 
and a risk equalisation scheme (Hamilton 2003; Ministry of Health Welfare and Sport 
2005). 
 
Before the private system came into force, concerns about relying on article 54 to 
justify such extensive regulation prompted the Dutch Minister of Health to request 
clarification from the (then) Commissioner for the Internal Market Frits Bolkestein 
(Hoogervorst 2003). In his response, Bolkestein notes that the private system cannot 
be excluded from the scope of the Directive as the insurers involved are carrying out 
‘an insurance activity’. However, the regulatory measures can be justified under 
article 54 because the system, though private, constitutes a complete alternative to 
statutory health insurance and the regulations (with some caveats; see below) ‘appear 
necessary to ensure legitimate objectives pursued by the Dutch government’ 
(Bolkestein 2003: 2). The Commission has recently confirmed this position in 
response to written questions put forward by Members of the European Parliament 
(McCreevy 2005; McCreevy 2006). 
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Bolkestein goes on to point out that it would not be proportionate to apply the 
proposed regulatory measures ‘to any complementary insurance cover offered by 
private insurers which goes beyond the basic social security package of cover laid 
down by the legislation’ (Bolkestein 2003: 3). His letter strongly suggests that ‘partial 
or complete alternative’ can be understood in terms of the benefits provided by a 
particular insurance scheme. Substitutive private health insurance constitutes an 
alternative to statutory cover because it replaces statutory benefits for those who are 
excluded from some aspects of the statutory system (higher earners in the Netherlands 
and Ireland) or those who are allowed to choose statutory or private cover (higher 
earners in Germany). Whether the substitutive cover is a partial or complete 
alternative depends, presumably, on whether the benefits it provides are ‘partial’ 
(cover of mainly outpatient care in Ireland) or ‘complete’ (cover of outpatient and 
inpatient care in Germany and the Netherlands). Conversely, complementary and 
supplementary cover cannot be construed as alternatives to statutory cover because 
they offer benefits in addition to those offered by the statutory system. Therefore 
private health insurance is only eligible for material regulation if it covers benefits 
offered by statutory health insurance. 
 
But ‘partial alternative’ could be interpreted in other ways. For example, the logic 
behind allowing governments to intervene in substitutive markets is implicitly based 
on the assumption that purely financial regulation of private insurers’ solvency levels 
will suffice for the purposes of consumer protection but will not be enough to ensure 
access to health care when private cover fulfils a social protection function. If this is 
the case, what are the implications for regulation of non-substitutive private health 
insurance that also fulfils this function? 
 
Where the statutory benefits package (the basic social security package of cover 
mentioned by Bolkestein) is relatively narrow or subject to extensive co-payments, it 
could be argued that individuals do not have full protection from financial risks 
associated with ill health unless they purchase complementary private health 
insurance covering excluded (and effective) services and / or statutory user charges. 
In such cases complementary cover provides a degree of social protection, thereby 
justifying material regulation to prevent private insurers from selecting risks, but rules 
to ensure affordable access to private cover might contravene the Directive. 
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Markets for complementary cover are likely to develop and expand in future, 
particularly in the context of constraints on public funding. Policy makers 
increasingly put forward the idea of offering a defined and more restricted package of 
statutory benefits (perhaps based on proven cost-effectiveness), usually on the 
understanding that the statutory package can be complemented by voluntary take-up 
of private insurance covering less effective and non-cost-effective services. In 
practice, however, efforts to set priorities and measure cost-effectiveness tend to be 
limited by technical, financial and political considerations, making it easier for 
governments to exclude whole areas of service, such as primary care, outpatient drugs 
or dental care, than single interventions of low cost-effectiveness (Ham and Robert 
2003). This means that complementary insurance often covers a range of necessary 
and cost-effective services. 
 
Governments in some countries have resorted to introducing or raising user charges to 
supplement public resources, again under the assumption that complementary cover 
will bridge the funding gap. In France the proportion of the population covered by 
private health insurance reimbursing statutory user charges grew from 33% in 1960 to 
86% in 2000 and accounts for about 13% of total expenditure on health (Sandier et al 
2004). Complementary cover of statutory user charges introduced in Slovenia in 1993 
now covers around 70% of the population and accounts for over 11% of total health 
expenditure (Albreht et al 2002). Recognising that this type of private cover 
contributes significantly to social protection, the French government has paid for 
complementary cover for people with low incomes since 2000, raising the proportion 
of the population covered to over 90%, while the Slovenian government enacted 
legislation in 2005 to require private insurers to offer open enrolment and community-
rated policies accompanied by a risk equalisation scheme (see below). 
 
The lack of a definitive interpretation of partial or complete alternative creates further 
uncertainty when we consider what happens if a particular market for health insurance 
changes from playing a substitutive to a complementary role. In Ireland, for example, 
private health insurance developed at a time when entitlement to publicly-funded 
inpatient and outpatient care was restricted to low-income households. A significant 
proportion of the population could only access health services by paying out of pocket 
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or buying private cover, which is why, when the Irish market was liberalised in 1994, 
private insurers were subject to quite stringent regulation (see below). However, the 
level of public benefits has gradually increased so that low-income households and all 
those aged 70 and over have free access to all types of care, while non-elderly higher-
income households have access to services that are predominantly publicly-funded but 
subject to co-payments up to a maximum of €550 per year (McDaid and Wiley 2006). 
In 2006 the government further increased the number of people eligible for free 
primary care (Department of Health and Children 2006). The regulatory framework 
originally justified under article 54.1 could now be questioned on the grounds of 
whether or not private health insurance in Ireland still constitutes a partial or complete 
alternative to statutory health insurance. In other words, it is debatable whether the 
Irish market for private health insurance continues to play a significant role in 
providing social protection. 
 
Material regulation that hinges on Bolkestein’s distinction between ‘basic’ and 
complementary or supplementary cover may also be problematic if the latter is 
offered by the same insurers responsible for providing statutory health insurance. 
Insurers could take advantage of the absence of regulation governing access to private 
cover to exploit consumers through the practice of conditional sale (that is, 
terminating a voluntary contract if an individual moves to a rival insurer for statutory 
cover). Although conditional sale poses a barrier to competition and is likely to 
infringe competition rules, it has been problematic in the Netherlands (Mossialos and 
Thomson 2004). 
 
How can governments intervene? 
The second area of uncertainty concerns the types of intervention that might be 
considered necessary and proportional. Article 54.2 and recitals to the Directive list 
the legal provisions governments can introduce where private cover provides a partial 
or complete alternative to statutory cover. However, it is not clear if the list should be 
understood as being exhaustive, in which case unlisted interventions would 
contravene the Directive; and again, there is the problem of interpreting partial or 
complete alternative. In this section we discuss interventions that have been disputed 
or may be contentious. 
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Financial transfers 
Risk equalisation schemes are a direct form of intervention typically involving 
financial transfers from insurers with low risks to insurers with high risks. They are 
intended to ensure access and fair competition by lowering incentives for insurers to 
select risks in markets with open enrolment and community-rated premiums (van de 
Ven and van Vliet 1992; Puig-Junoy 1999), but their existence has been challenged in 
the Netherlands, Ireland and Slovenia. 
 
Bolkestein’s letter raised concerns that the Dutch government’s risk equalisation 
scheme, part-financed from public funds, might contravene EU rules about state aid 
(Bolkestein 2003: 3), but the Commission has now authorised the transfer of public 
funds as, in its opinion, the aid does not unduly distort competition (European 
Commission 2005; McCreevy 2005). Nevertheless, the fact that a regulatory measure 
specifically mentioned in the Directive as permissible under article 54.1 could be seen 
to be contentious, even when it has been agreed that the Dutch system is a ‘complete 
alternative’, reinforces the potential for confusion. Despite further assurances from the 
European Commissioner for Competition (Reerink and Rosenberg 2005), Dutch 
analysts and politicians continue to question the legality of the risk equalisation 
scheme, noting that the ECJ will have the final say on whether or not the scheme is 
both necessary and proportionate (den Exter 2005; Meijer and Liotard 2005). 
 
Risk equalisation in Ireland has been the subject of a complaint to the European 
Commission (even though it does not involve public funds) on the grounds that 
financial transfers between private insurers would constitute a form of state aid to the 
largest private insurer in the market. Prior to liberalisation in 1994 private health 
insurance in Ireland was mainly provided by Vhi Healthcare, a quasi-public body 
under the jurisdiction of the Department of Health. By 1994 Vhi Healthcare covered 
about 37% of the population (Department of Health and Children 1999). After 
liberalisation the Irish government relied on article 54 to maintain the existing 
regulatory framework which required insurers to offer open enrolment, community-
rated premiums, minimum benefits and lifetime cover. The government also passed 
new legislation allowing it to establish a risk equalisation scheme to be activated by 
the government at the request of the independent Health Insurance Authority (HIA) if 
it became evident that private insurers were competing through risk selection rather 
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than on the basis of administrative efficiency and quality (Department of Health and 
Children 1999). 
 
BUPA Ireland (a branch of the UK insurer BUPA), the larger of the two private 
insurers currently operating in the Irish market, lodged a complaint with the 
Commission in 1998, arguing that the risk equalisation scheme was a form of state aid 
that distorted competition and discouraged cost containment in the health sector 
(BUPA Ireland 2003). In response, the Irish government argued that the Directive 
allowed member states to exercise reasonable discretion with respect to the general 
good and that the scheme had particular regard for the need for proportionality 
(Department of Health and Children 2001). Five years later the Commission issued a 
decision stating that financial transfers made under the scheme would not constitute 
state aid for two reasons. First, the scheme would legitimately compensate insurers for 
obligations they faced in carrying out a service of general economic interest; and 
second, this compensation is limited to what is necessary and proportionate to ensure 
stability in a community-rated market for private health insurance (European 
Commission 2003). The decision also noted that the scheme would not distort 
competition, penalise efficiency or create perverse incentives that might lead to cost 
inflation, nor was it likely to deter insurers from entering the market as new entrants 
can exclude themselves from the scheme for a period of up to three years. Even if 
financial transfers were to be considered a form of state aid, the Commission pointed 
out that this aid would not, by itself, amount to a violation of the Directive. 
 
The Commission’s decision is as noteworthy for what it abstains from commenting on 
as for what it confirms. It explicitly states that it assessed the risk equalisation 
scheme’s compatibility with state aid rules ‘without prejudice to the analysis of its 
compatibility with other relevant EU rules, and in particular with [the Directive]’, 
emphasising that it was made independently of any consideration as to whether the 
Irish market could be regarded as a partial or complete alternative to cover provided 
by the statutory system (European Commission 2003: 8). 
 
BUPA Ireland subsequently challenged the Commission’s reluctance to consider 
whether the scheme infringed the Directive. Asking the ECJ to suspend the decision, 
it accused the Commission of misapplying the public service compensation test, 
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wrongly identifying open enrolment, community rating, minimum benefits and 
lifetime cover as public service obligations when they actually represent rules 
generally applied to all insurers offering private health insurance (European Court of 
Justice 2003). It also accused the Commission of failing to consider whether these 
obligations imposed a financial burden on Vhi Healthcare and whether the risk 
equalisation scheme would affect the development of trade contrary to the interests of 
the Community, and of failing to initiate a formal investigation procedure, given the 
complexity of the arguments and the economic analysis required. The Dutch and Irish 
governments and Vhi Healthcare have joined the legal proceedings in defence of the 
Commission and the issue has yet to be resolved. In December 2005 the Irish Minister 
of Health, acting on advice from the HIA, announced her intention to introduce risk 
equalisation from January 2006. BUPA Ireland and BUPA Insurance are challenging 
the legality of the scheme under Irish and European law (The Irish Times 2006). 
 
The Irish proceedings will be of interest in Slovenia, where two out of the three 
insurance companies operating in the private health insurance market have challenged 
new legislation establishing a risk equalisation scheme. The largest insurer Vzajemna 
(a mutual association,) argued that the scheme would favour the two other 
(commercial) insurers and encourage risk selection, while the larger commercial 
insurer Adriatic argued that the scheme would distort competition (Adriatic 2005; 
Vzajemna 2005; Milenkovic 2006). Although the Slovenian High Court ruled in the 
government’s favour in November 2005 (Toplak 2005), further legal challenges at 
national and EU level are possible, given that private health insurance in Slovenia 
plays an unarguably complementary role. 
 
Other forms of financial transfer include direct or indirect cross-subsidies. In the 
Netherlands there has been some discussion about the legality of two cross-subsidies 
that applied prior to 2006: one from privately- to publicly-insured individuals, 
designed to compensate the statutory health insurance scheme for covering a 
disproportionate number of older people (the MOOZ scheme); and another from the 
privately insured under 65 years of age to cover the costs of standardised benefits and 
fixed prices for privately-insured individuals over 65 years old or in poor health (the 
WTZ scheme). In 2000 an independent advisory body suggested that these cross-
subsidies contravened the Directive (Raad voor de Volksgezondheid en Zorg 2000), 
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but other analysts have argued that if the MOOZ contributions were regarded as a 
form of earmarked tax on private health insurance, they would fall under the fiscal 
competence of the Dutch government and would therefore be beyond the scope of the 
Directive (Palm 2002). 
 
Benefits 
Governments can regulate the benefits offered by private insurers by specifying a 
minimum level or standard package of benefits and / or requiring benefits to be 
provided in kind rather than in cash. The first intervention aims to facilitate price 
competition, while both aim to lower financial barriers and ensure access to a given 
range of health services. 
 
Minimum or standard benefits 
The Commission expected the single market in insurance to stimulate competition 
among insurers, precipitating efficiency gains and bringing consumers the benefits of 
wider choice and lower prices (European Commission 1998). A preamble to the 
Directive states that it is in policyholders’ interest that they should have access to ‘the 
widest possible range of insurance products available in the Community so that [they] 
can choose that which is best suited to [their] needs’ (European Communities 1992). 
 
In theory, product differentiation benefits consumers by providing policies tailored to 
meet particular needs and benefits insurers by allowing them to distinguish between 
high and low risk individuals. In practice, it may be detrimental to consumers in two 
ways. First, it gives insurers greater opportunity to select risks, leading to access 
problems for high risks. Second, making consumers choose from a wide range of 
highly differentiated products severely restricts competition, which only operates 
effectively where consumers find it easy to make informed comparisons about price 
and quality. 
 
To encourage competition based on price and quality (rather than risk selection), 
regulators can require insurers to offer a standard package of benefits, use 
standardised terms when marketing products, inform potential and existing policy 
holders of all the price and product options open to them and provide consumers with 
access to centralised sources of comparable information. However, the Directive 
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specifically outlaws product and price controls except where private health insurance 
constitutes a partial or complete alternative to statutory cover, and even in these 
circumstances control is limited to offering benefits standardised in line with statutory 
benefits; that is, the primary aim is to ensure that the privately insured have access to 
the same services as the publicly insured rather than to facilitate price competition. 
For example, governments in Germany and the Netherlands have required private 
insurers to offer older policy holders benefits that match statutory benefits (Mossialos 
and Thomson 2004). 
 
In the absence of product regulation, liberalisation of health insurance markets in 
some member states has been accompanied by rising levels of product differentiation, 
with evidence suggesting that consumers may be confused by the proliferation of 
products on offer (Mossialos and Thomson 2004). For example, an official 
investigation into information problems in the market for supplementary private 
health insurance in the United Kingdom found that increased product complexity did 
not benefit consumers; rather, consumers sometimes paid more than they should and 
often purchased inappropriate policies (Office of Fair Trading 1998). An OECD study 
noted that as the diversity of schemes in the UK market rose, consumers faced 
increasing difficulty in comparing premiums and products, a concern echoed by 
consumer bodies in other member states (Organisation for Economic Co-operation 
and Development 2001). 
 
Perhaps due to limited price competition and private insurers’ limited ability to 
control costs, prices appear to have gone up rather than down in many member states. 
Research based on data from several member states shows that, during the 1990s, the 
compound annual growth rate of private health insurance premiums rose much faster 
than the average annual growth rate of total spending on health care (Mossialos and 
Thomson 2004). 
 
Benefits in kind 
The provision of benefits in kind enhances social protection by removing financial 
barriers to accessing health care. Bolkestein’s letter suggests that the Dutch 
government’s proposed requirement for insurers offering substitutive private health 
insurance to provide a basic package of benefits in kind could infringe the free 
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movement of services by creating barriers for non-Dutch insurers entering the market 
and might need to be assessed for proportionality and necessity (Bolkestein 2003: 3). 
This raises concerns not only for the new Dutch system, but for statutory and 
substitutive private health insurance in other member states. 
 
Differential treatment of insurers 
Under the Directive governments can no longer influence market structure (by 
restricting the provision of private health insurance to a single approved insurer or to 
statutory health insurance funds) or discriminate against particular types of insurer. 
For example, recitals to the Directive outlaw regulation preventing non-specialist or 
composite insurers from providing health insurance. When the German government 
transposed the Directive it had to abolish its rule excluding non-specialist insurers 
from entering the private health insurance market, but used its social law to prohibit 
employers’ from contributing to policies offered by composite insurers, leading the 
Commission to refer Germany to the ECJ (European Court of Justice 2001). 
 
National laws often distinguish between non-profit and for-profit institutions, 
sometimes resulting in preferential treatment of non-profit institutions, notably mutual 
associations, which have a long history of involvement in statutory and private health 
insurance in many member states, traditionally operating in different areas of the 
market from commercial insurers (Palm 2002). The special status accorded to mutual 
associations has given rise to difficulties under the Directive. For example, French 
mutual associations operate under a special ‘Code de la Mutualité’, which means they 
are subject to less rigorous rules on financial and prudential accountability than 
commercial insurers or provident associations (Palm 2002). Following a ruling by the 
ECJ the French government was forced to adopt a revised code tightening the 
solvency requirements for mutual associations and bringing national law in line with 
the Directive (European Court of Justice 1999; European Commission 2000). 
 
Tax incentives in France, Belgium and Luxembourg favour mutual or provident 
associations over commercial insurers. The French government contravened the 
Directive by exempting mutual and provident associations from paying insurance 
premium tax (Mossialos and Thomson 2004). In 1993 the French Federation of 
Insurance Companies lodged two complaints against the French government for this 
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discriminatory tax policy. Their complaints were eventually upheld by the 
Commission in November 2001 and the French government was asked to abolish the 
tax exemptions in question. The Commission noted that while it recognised the 
specific role of mutual associations in providing services of general economic interest, 
it considered that the tax advantages granted to them were disproportionate to the 
burden they bore in undertaking such services, which only represented a small share 
of their activities (Palm 2002). However, the Commission allowed the government to 
continue to make selective corporate tax provisions for non-profit organisations, as 
this was considered to be a normal part of the fiscal system. In Luxembourg the 
existence of a ‘gentleman’s agreement’ between mutual associations and commercial 
insurers has prevented the latter from complaining about preferential tax treatment 
(Mossialos and Thomson 2004). The agreement rests on the understanding that 
mutual associations will not encroach on commercial insurers’ dominance of the 
market for pensions and other types of insurance. 
 
Some argue in favour of treating mutual associations differently on the grounds that 
they provide better access to health services because they offer open enrolment, 
lifetime cover and community-rated premiums, whereas commercial insurers restrict 
access by rejecting applications, excluding the cover of pre-existing conditions and 
risk rating premiums (Rocard 1999; Palm 2002). In a market where mutual 
associations and commercial insurers operate side by side the latter may be able to 
undermine the former by attracting low risks with lower premiums, leaving mutual 
associations to cover high risks. However, while the distinction between non-profit 
and for-profit insurers is important in so far as an insurer’s profit status determines its 
motivation and influences its conduct, in practice there is considerable variation in the 
way in which mutual associations behave; in some member states their conduct may 
be indistinguishable from the conduct of commercial insurers. As it is not possible to 
make assumptions about an insurer’s conduct on the basis of its legal status it would 
be more appropriate to discriminate on the basis of conduct, favouring insurers who 
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4.  Discussion and conclusions 
 
The EU regulatory framework established by the Directive places limits on national 
competence in the area of private health insurance. It relies on financial regulation to 
protect consumers, prohibiting material regulation such as price and product controls 
except where private cover constitutes a complete or partial alternative to statutory 
health insurance and so long as any intervention is necessary, proportionate and non-
discriminatory. 
 
There is no agreement as to what is meant by partial or complete alternative and the 
absence of a definition or guidance from the Commission has led to uncertainty and 
confusion among policy makers, regulators and insurers. Where the Commission has 
had opportunity to clarify this aspect of the Directive it has often sidestepped the 
issue, relying instead on rules about services of general economic interest to authorise 
(Ireland) or prohibit (France) government intervention. A key exception is 
Bolkestein’s letter, in which he argues that article 54.1 ought not to be used to justify 
material regulation of complementary private health insurance. 
 
Bolkestein’s definition of complementary cover fails to recognise that this type of 
private health insurance increasingly contributes to social protection for those who 
purchase it, operating in an unofficial partnership with statutory health insurance 
where it offers reimbursement of statutory user charges and / or provides access to 
effective health services excluded from the statutory benefits package. In particular, 
complementary cover of statutory user charges tends to be purchased by a relatively 
high proportion of the population, making it regressive in financing health care 
(because it is not restricted to richer groups) and creating inequalities in access to 
health care (Wagstaff et al 1999). 
 
If, as we have argued, the logic underlying article 54.1 is to permit material regulation 
where private health insurance fulfils a social protection function, then in either case 
obliging complementary insurers to offer open enrolment and community rating 
would be necessary to ensure equitable access to health care, while a risk equalisation 
scheme might be needed to lower incentives to select risks and to encourage 
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competition based on price and quality. The Irish experience highlights the 
complexity of the issues at stake and the difficulty caused by legal uncertainty. 
 
In markets where private health insurance does not contribute to social protection the 
Directive assumes that financial regulation will be sufficient to protect consumers, but 
we have argued that solvency rules alone may not be adequate if health insurance 
products are highly differentiated. Information asymmetry exacerbated by product 
differentiation appears to be a growing problem in markets across the European Union 
and the Commission has not yet put in place mechanisms for monitoring anti-
competitive behaviour by insurers. 
 
Communications from the Commission have raised doubts about the compatibility of 
certain regulatory measures with competition rules; for example, the provision of 
benefits in kind. More attention should be paid to this issue, which could have 
significant implications for statutory as well as private health insurance. 
 
The Directive reflects the regulatory norms of its time. When it was introduced in 
1992 the Commission may have been convinced that it would provide ample scope 
for governments to protect consumers where necessary and would not jeopardise 
statutory arrangements. Article 54 would protect markets contributing to social 
protection, while in markets regarded as supplementary, the benefits of de-regulation 
(increased choice and competition resulting in lower prices) would outweigh concerns 
about consumer protection. 
 
These assumptions are more problematic now, partly because there is no evidence to 
suggest that the expected benefits of competition have, as yet, materialised. Private 
health insurance premiums in many member states have risen rather than fallen in 
recent years, often faster than inflation in the health sector as a whole, while insurers’ 
expansion across national borders has been limited to cross-border mergers and 
acquisitions rather than genuinely new entrants to the market (Mossialos and 
Thomson 2004). The assumptions are also problematic due to increased blurring of 
the boundaries between normal economic activity and social security; the latter is no 
longer the exclusive preserve of statutory institutions or public finance, a development 
likely to bring new challenges for policy makers. 
  24 
References 
Adriatic (2005). [Dispute put forward to high court regarding the new health care and 
health insurance Act no. U-I-282/05-1, 10 October 2005]. Ljubljana, Adriatic, d.d. 
 
Albreht, T., M. Cesen, D. Hindle, E. Jakubowski, B. Kramberger, V. K. Petric, M. 
Premik and M. Toth (2002). Health care systems in transition: Slovenia. Copenhagen, 
European Observatory on Health Systems and Policies. 
 
Association Internationale de la Mutualité (1999). "Towards a fourth generation of 
European insurance directives?" Aims (newsletter of the Association Internationale de 
la Mutualité) 5(March): 1-3. 
 
Barr, N. (1998). The economics of the welfare state (3rd edition). Oxford, Oxford 
University Press. 
 
Bolkestein, F. (2003). Letter from the European Commission to the Dutch Minister of 
Health, Welfare and Sport, 25 November 2003. The Hague, Ministry of Health, 
Welfare and Sport. 
 
BUPA Ireland (2003). Risk equalisation. Dublin, BUPA Ireland. 
 
den Exter, A. (2005). Blending private and social health insurance in the Netherlands.  
Access to care, access to justice: the legal debate over private health insurance in 
Canada. C. M. Flood, K. Roach and L. Sossin. Toronto, University of Toronto Press. 
 
Department of Health and Children (1999). Private health insurance, White Paper. 
Dublin, Government of Ireland. 
 
Department of Health and Children (2001). Submission to the European 
Commission's study on voluntary health insurance in the European Union. Dublin, 
Department of Health and Children. 
 
Department of Health and Children (2006). Press release: Tánaiste announces 
increase in means test for GP Visit Card, 26 June 2006, 
  25 
http://www.dohc.ie/press/releases/2006/20060626.html, accessed 21 July 2006. 
Dublin: Department of Health and Children. 
 
European Commission (1998). "Liberalisation of insurance in the single market: 
update and questions." Single Market News 11: 1-8. 
 
European Commission (2000). Freedom to provide services and the general good in 
the insurance sector, Commission interpretive communication C(1999)5046, 2 
February 2000. Brussels, European Commission. 
 
European Commission (2000). Insurance: Commission launches new infringement 
proceedings against France concerning mutual benefit companies (press release 11 
May 2000). Brussels, European Commission. 
 
European Commission (2000). Insurance: infringement proceedings against France 
concerning mutual societies and the requirement of a marketing information sheet  
(press release 28 July 2000). Brussels, European Commission. 
 
European Commission (2003). State Aid N 46/2003 - Ireland - Risk equalisation 
scheme in the Irish health insurance market. Brussels, European Commission. 
 
European Commission (2005). State aid: Commission endorses €15 billion public 
funding for new Dutch health insurance system, IP/05/531, Brussels 3rd May 2005. 
 
European Communities (1973). "First Council Directive 73/239/EEC of 24 July 1973 
on the coordination of laws, regulations and administrative provisions relating to the 
taking-up and pursuit of the business of direct insurance other than life assurance." 
OJEC L 228(16 August 1973): 3-19. 
 
European Communities (1988). "Second Council Directive 88/357/EEC of 22 June 
1988 on the coordination of laws, regulations and administrative provisions relating to 
direct insurance other than life assurance and laying down provisions to facilitate the 
effective exercise of freedom to provide services and amending Directive 
73/239/EEC." OJEC L 172(4 July 1988): 1. 
  26 
European Communities (1992). "Council Directive 92/49/EEC of 18 June 1992 on the 
coordination of laws, regulations and administrative provisions relating to direct 
insurance other than life assurance and amending Directives 73/239/EEC and 
88/357/EEC (Third non-life insurance directive)." OJEC L 228(11 August 1992): 1-
23. 
 
European Court of Justice (1991). Case C-41/90, 23 April 1991, Höfner and Elser v 
Macrotron. 
 
European Court of Justice (1999). Case C-239/98, 16 December 1999, Commission v 
France. 
 
European Court of Justice (2000). Case C-206/98, 18 May 2000, Commission v 
Belgium. 
 
European Court of Justice (2000). Case C-296/98, 11 May 2000, Commission v 
France. 
 
European Court of Justice (2001). Case C-298/01, Pending Case, Commission v 
Germany. 
 
European Court of Justice (2003). Case T-289/03, 19 August 2003, British United 
Provident Association Limited, BUPA Insurance Limited and BUPA Ireland Limited. 
 
Ham, C. and G. Robert, Eds. (2003). Reasonable rationing: international experience 
of priority setting in health care. Buckingham, Open University Press. 
 
Hamilton, G. J. (2003). "Private insurance for all in the Dutch health care system?" 
European Journal of Health Law 10(1): 53-61. 
 
Hatzopoulos, V. (2002). Do the rules on internal market affect national health care 
systems? The impact of EU law on health care systems. M. McKee, E. Mossialos and 
R. Baeten. Brussels, P.I.E.-Peter Lang. 
  27 
Hoogervorst, H. (2003). Letter from the Dutch Minister of Health, Welfare and Sport 
to the European Commissioner for the Internal Market, 19 December 2003. The 
Hague, Ministry of Health, Welfare and Sport. 
 
Maarse, H. (2002). "Health insurance reform (again) in the Netherlands: will it 
succeed?" Euro Observer 4(3): 1-3. 
 
Mabbett, D. (2000). "Social regulation and the social dimension in Europe: the 
example of insurance." European Journal of Social Security 2(3): 241-257. 
 
McCreevy, C. (2005). E-3829/05EN. Answer given by Mr McCreevey on behalf of 
the Commission (12 December 2005). Strasbourg, European Parliament. 
 
McCreevy, C. (2006). E-3830/05EN. Answer given by Mr McCreevey on behalf of 
the Commission (24 January 2006). Strasbourg, European Parliament. 
 
McDaid, D. and M. M. Wiley (2006). Health care systems in transition: Ireland. 
Copenhagen, European Observatory on Health Systems and Policies. 
 
Meijer, E. and K. Liotard (2005). Written question to the European Commission E-
3829/05 (11 October 2005). Entry into force in 2006 of a new Care Insurance Act in 
the Netherlands and its relationship with competition policy and the common market: 
II. Acceptance and equalisation. Strasbourg, European Parliament. 
 
Merkin, R. and A. Rodger (1997). EC insurance law. London, Longman. 
 
Milenkovic, A. (2006). Health insurance in Slovenia, unpublished report. 
 
Ministry of Health Welfare and Sport (2005). Do you have compulsory or private 
health insurance? A single new-style health insurance for everybody as of 1 January 
2006. The Hague, Ministry of Health, Welfare and Sport. 
 
Mossialos, E. and M. McKee (2002). "Health care and the European Union." British 
Medical Journal 324(7344): 991-2. 
  28 
Mossialos, E. and S. Thomson (2004). Voluntary health insurance in the European 
Union. Copenhagen, World Health Organization. 
 
Nemeth, K. (2001). European insurance law: a single insurance market? EUI Working 
Paper LAW No 2001/4. Florence, European University Institute. 
 
Office of Fair Trading (1998). Health insurance: a second report by the Office of Fair 
Trading. London, Office of Fair Trading. 
 
Organisation for Economic Co-operation and Development (2001). Private health 
insurance in OECD countries: compilation of national reports. Paris, OECD. 
 
Organisation for Economic Co-operation and Development (2003). Health Data 2003. 
Paris, Organisation for Economic Co-operation and Development. 
 
Palm, W. (2002). Voluntary health insurance and EU insurance directives: between 
solidarity and the market. The impact of EU law on health care systems. M. McKee, 
E. Mossialos and R. Baeten. Brussels, P.I.E.-Peter Lang. 
 
Puig-Junoy, J. (1999). "Managing risk selection incentives in health sector reforms." 
International Journal of Health Planning and Management 14: 287-311. 
 
Raad voor de Volksgezondheid en Zorg (2000). De Rollen Verdeeld: Burger, 
Ondernemer en Overhedi in de Gezondheidszorg [Division of roles: citizen, 
entrepreneur and government in health care]. Zoetermeer, Raad voor de 
Volksgezondheid en Zorg. 
 
Reerink, A. and E. Rosenberg (2005). Neelie Kroes over staatssteun aan nieuwe 
zorgstelsel [Neelie Kroes on state aid to the new health care scheme] (5 October). 
NRC Handelsblad. Rotterdam. 
 
Rice, T. (2001). "Individual autonomy and state involvement in health care." Journal 
of Medical Ethics 27: 240-244. 
  29 
Rocard, M. (1999). Mission mutualité et droit communautaire: rapport de fin de 
mission. Paris, Government of France. 
 
Rupprecht, F., B. Tissot and F. Chatel (2000). "German health care system: promoting 
greater responsibility among all system players." INSEE Studies 42(January 2000). 
 
Sandier, S., D. Polton, V. Paris, S. Thomson and E. Mossialos (2004). Health care 
systems in transition: France. Copenhagen, European Observatory on Health Systems 
and Policies. 
 
Schoen, C., M. M. Doty, S. R. Collins and A. L. Holmgren (2005). "Insured but not 
protected: how many adults are underinsured?" Health Affairs Web Exclusive June 
14. 
 
The Irish Times (2006). Bupa claims it faces €161m risk equalisation bill over three 
years. The Irish Times. Dublin. 
 
Toplak, S. (2005). Constitutional Court failed to please Vzajemna and Adriatic. 
http://www.finance-on.net/show.php?id=137526 (accessed 17 November 2005). The 
Finance Business Daily Newspaper. Ljubljana. 
 
van de Ven, W. P. M. M. and R. van Vliet (1992). How can we prevent cream 
skimming in a competitive health insurance market? The great challenge for the 90s. 
Health economics worldwide. P. Zweifel and H. Frech III. Amsterdam, Kluwer. 
 
Vzajemna (2005). [Dispute put forward to high court regarding the new health care 
and health insurance Act no. U-I-277/05, 22 December 2005]. Ljubljana, Vzajemna, 
d.v.z. 
 
Wagstaff, A., E. van Doorslaer, H. van der Burg, S. Calonge, T. Christiansen, G. 
Citoni, U. G. Gerdtham, M. Gerfin, L. Gross, U. Hakinnen, P. Johnson, J. John, J. 
Klavus, C. Lachaud, J. Lauritsen, R. Leu, B. Nolan, E. Peran, J. Pereira, C. Propper, 
F. Puffer, L. Rochaix, M. Rodriguez, M. Schellhorn and O. Winkelhake (1999). 
  30 
"Equity in the finance of health care: some further international comparisons." 
Journal of Health Economics 18(3): 263-90. 
 
Wasem, J. (1995). Regulating private health insurance markets. Four country 
conference on health care reforms and health care policies in the United States, 
Canada, Germany and the Netherlands, Amsterdam, February 23-25 1995. K. Okma. 
Amsterdam, Ministry of Health, Welfare and Sport. 
 
White, R. (1999). EC social security law. Harlow, Longman. 
 
